

Mechanisms, diagnosis and management of hepatic encephalopathy

Ravi Prakash and Kevin D. Mullen

Abstract | Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of both acute and chronic liver disease. Symptoms of HE can include confusion, disorientation and poor coordination. A general consensus exists that the synergistic effects of excess ammonia and inflammation cause astrocyte swelling and cerebral edema; however, the precise molecular mechanisms that lead to these morphological changes in the brain are unclear. Cerebral edema occurs to some degree in all patients with HE, regardless of its grade, and could underlie the pathogenesis of this disorder. The different grades of HE can be diagnosed by a number of investigations, including neuropsychometric tests (such as the psychometric hepatic encephalopathy score), brain imaging and clinical scales (such as the West Haven criteria). HE is best managed by excluding other possible causes of encephalopathy alongside identifying and the precipitating cause, and confirming the diagnosis by a positive response to empiric treatment. Empiric therapy for HE is largely based on the principle of reducing the production and absorption of ammonia in the gut through administration of pharmacological agents such as rifaximin and lactulose, which are approved by the FDA for the treatment of HE.

Prakash, R. & Mullen, K. D. *Nat. Rev. Gastroenterol. Hepatol.* 7, 515–525 (2010); published online 10 August 2010; doi:10.1038/nrgastro.2010.116

MedscapeCME[®] Continuing Medical Education online

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Nature Publishing Group. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at <http://www.medscapecme.com/journal/nrgastro>; and (4) view/print certificate.

Learning objectives

Upon completion of this activity, participants should be able to:

- 1 Describe the types and patterns of hepatic encephalopathy (HE) and risk factors for the development of both minimal and overt HE.
- 2 Construct an appropriate diagnostic assessment for patients with suspected HE that addresses a valid differential diagnosis.
- 3 Develop treatment strategies for HE that incorporate pharmacologic and nonpharmacologic therapies.

Competing interests

K. D. Mullen declares an association with the following companies: Ocera Therapeutics and Salix Pharmaceuticals. See the article online for full details of the relationship. R. Prakash and the Chief Editor N. Wood declare no competing interests. The CME questions author D. Lie has served as a nonproduct speaker for “Topics in Health” for Merck Speaker Services.

Introduction

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of both acute and chronic liver disease.¹ This disease encompasses a broad range of neuropsychiatric abnormalities of varying severity: affected patients exhibit alterations in psychomotor, intellectual, cognitive, emotional, behavioral and fine motor functions. HE can be classified as either ‘overt’ or ‘minimal’. Overt HE (OHE) is a syndrome of neurological and neuropsychiatric abnormalities that can be detected by bedside clinical tests. By contrast, patients with minimal HE (MHE) present with normal mental and neurological status upon clinical examination but specific psychometric tests yield abnormal results. A classification system for HE disorders was devised by the Working Party at the 1998 World Congress of Gastroenterology in Vienna, Austria (Figure 1).¹ This classification has helped to standardize the nomenclature used in HE diagnosis and research worldwide, and has been used throughout this article.

Historically, the role of ammonia accumulation has dominated explanations of the pathogenesis of HE. Over the past decade, however, evidence has emerged for a role of other concurrent factors (such as inflammation and hyponatremia) in the development of HE.^{2–6} Some degree of cerebral edema occurs in all patients with HE, including those with MHE, and astrocyte swelling is thought to have a key role in the disease. The precise molecular mechanisms that cause these changes in the brain of patients with HE are, however, yet to be elucidated.

The burden of disease for cirrhosis is increasing, especially with regard to the rise in the number of patients with hepatitis C or nonalcoholic steatohepatitis. For this

Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA (R. Prakash, K. D. Mullen).

Correspondence to: K. D. Mullen (kevin.mullen@case.edu)

Key points

- Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of acute and chronic liver disease
- Inflammation and raised levels of ammonia in the blood (owing to diminished clearance of ammonia by the liver) underlie the pathogenesis of HE
- Some degree of cerebral edema is observed in all grades of HE
- The occurrence of any neuropsychiatric manifestation in patients with liver disease should be treated as HE unless proven otherwise
- An acute episode of HE is managed by a tripartite strategy: ruling out other causes of encephalopathy, identifying the precipitating cause and initiating empiric therapy
- Rifaximin and lactulose are the only two medications approved by FDA for long-term treatment of HE
- Work-up for liver transplantation must be initiated as early as possible




Figure 1 | Classification of hepatic encephalopathy (HE) proposed by the Working Party at the 1998 World Congress of Gastroenterology, Vienna, Austria. The Working Party proposed a classification system for HE to standardize the nomenclature used in HE diagnosis. HE can be graded into three types: type A HE is associated with acute liver failure; type B HE is found in patients with portosystemic bypass and no intrinsic hepatocellular disease; type C HE is associated with cirrhosis or portal hypertension or portosystemic shunts. Type C HE can be further divided into three categories: episodic HE (precipitated; spontaneous; recurrent); persistent HE (mild; severe; treatment-dependent); minimal HE.

reason, recognition of the complications of cirrhosis (including HE) and the need for improved management of patients affected by this disease is imperative.⁷⁻⁹ HE has a substantial negative effect on quality of life, even in patients with minimal disease.¹⁰ Prasad *et al.*¹¹ were the first group to show that treatment of MHE improves patients' quality of life. Moreover, patients with HE have poor navigational skills and an impaired ability to drive.¹²⁻¹⁵ This impairment places these individuals at an increased risk of road traffic violations and accidents.^{15,16} Apart from these negative effects on quality of life and daily functioning, patients with HE also have increased mortality.^{9,17} Furthermore, diagnosis of MHE has a prognostic implication with regard to the risk of progression

to OHE.¹⁷ With increased awareness and improved diagnostic methods, the burden of HE is likely to attain epidemic proportions. This Review therefore considers the pathogenesis, diagnosis and management of HE. The therapies that are effective in the treatment of HE are also discussed along with the available options for long-term management of this disorder.

Pathogenesis

The pathogenesis of HE has not been clearly defined. The general consensus is that elevated levels of ammonia and an inflammatory response work in synergy to cause astrocytes to swell and fluid to accumulate in the brain (cerebral edema), which is thought to explain the symptoms of HE. The precise molecular mechanisms that result in these morphological changes in the brain are yet to be identified.

Ammonia

Ammonia is a byproduct of the metabolism of nitrogen-containing compounds and is involved in a number of metabolic reactions. However, ammonia is toxic at elevated concentrations and must be removed from the body.^{18,19} In mammals, ammonia is most commonly eliminated through the formation of urea in the liver. This nontoxic metabolite is water soluble and can be excreted by the kidneys. In patients with acute liver failure, however, brain and muscle cells are involved in the metabolism of ammonia to a greater extent than normal.¹⁹ These 'ammonia sinks' utilize the amino acid glutamate to detoxify ammonia by converting it to glutamine.^{20,21}

Accumulation of ammonia has received considerable attention as an explanation for the pathogenesis of HE. In the early 18th century, Nencki, Pavlov and Zaleski demonstrated the development of neuropsychiatric changes in dogs after experimental portacaval fistula surgery (termed Eck fistula) induced the symptoms of HE.²² The neuropsychiatric symptoms worsened if the dogs were fed meat, which led to the term 'meat intoxication syndrome'.²³ Behavioral alterations in patients with liver dysfunction were formally described later in the 20th century by Phillips and colleagues.²⁴ In 1991, Lockwood and colleagues demonstrated direct evidence for the role of ammonia in the pathogenesis of HE by using radio-labeled nitrogen in PET imaging studies of patients with severe liver disease and MHE.²⁵

Astrocytes are the only cells in the brain that can metabolize ammonia.¹⁹ The enzyme glutamine synthetase (present in the endoplasmic reticulum of astrocytes) is responsible for the conversion of equimolar concentrations of glutamate and ammonia to glutamine.²¹ Intracellular levels of glutamine, therefore, increase enormously as the ambient ammonia concentrations rise owing to liver failure.²⁶ As glutamine is an osmolyte, water moves inside the astrocyte causing it to swell. This swelling leads to cerebral edema and intracranial hypertension.^{27,28} Administration of methionine sulfoximine (an inhibitor of glutamine synthase) prevents astrocyte swelling in experiments in animals.^{29,30} Sudden exposure of astrocytes to high concentrations of

ammonia *in vitro* (equivalent to the levels of ammonia in the brain observed during acute liver failure and thereby, type A HE) results in glutamate release.^{31–33} This release is thought to contribute to increased neuronal activity because glutamate is an excitatory neurotransmitter and is believed to be responsible for the clinical changes observed in patients with type A HE, including agitation, confusion, seizures and coma.

Low-grade cerebral edema and a predominantly neuro-inhibitory state (that is, slowing of mental processes) is pathognomonic of type C HE, which is associated with chronic liver disease (Figure 1).^{34–36} In astrocytes, prolonged exposure to increased concentrations of ammonia induces a number of changes. Astrocyte swelling is, in part, compensated for by release of the osmolytes myoinositol and taurine from inside the cell.³⁴ This homeostatic mechanism results in depletion of intracellular myoinositol stores; low intracellular myoinositol levels are associated with an increased risk of sudden deterioration of HE.³⁷ The activity of glutamate receptors in the postsynaptic plate are downregulated and glutamate transporters on the astrocyte cell membrane are inactivated.³⁸ Over time, some of these cells change in shape and form and become 'Alzheimer type II' astrocytes, as observed in both *in vitro* studies and in human autopsy specimens.^{39,40}

Inflammation

Ammonia dysmetabolism cannot single-handedly explain all the neurological changes that are seen in patients with HE.⁴¹ Sepsis is a well-known precipitating factor for decompensation of liver disease in a previously stable patient with cirrhosis (a process now termed acute-on-chronic liver failure). Shawcross *et al.*³ studied the effect of induced hyperammonemia in a group of patients with cirrhosis who were admitted to hospital with systemic inflammatory response syndrome (SIRS).³ Patients with SIRS who were given an oral amino acid solution to induce hyperammonemia achieved worse psychometric test results. However, once SIRS (and the infection) had been successfully treated, and patient's levels of the inflammatory markers tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6 had returned to normal, their psychometric test results did not deteriorate after hyperammonemia was induced.³ Similar results were obtained when a large population of patients with cirrhosis underwent blood tests (to measure levels of ammonia and inflammatory markers) and psychometric assessment.² The presence and severity of MHE were independent of both serum levels of ammonia and the severity of liver disease; however, serum levels of inflammatory markers (such as C-reactive protein, white blood cell count, IL-6) were much higher in patients with MHE than in patients without MHE.²

The peripheral immune system communicates with the brain in response to infection and inflammation. Astrocytes and microglial cells release cytokines in response to injury or inflammation.⁴² Findings from studies in rats have indicated that the rise in blood levels of TNF that occurs during inflammation stimulates glial

cells to secrete the cytokines IL-1 and IL-6.⁴³ TNF also compromises the endothelial blood–brain barrier and IL-1 β affects the integrity of the glial side of the blood–brain barrier.^{44,45} Both TNF and IL-6 enhance fluid–phase permeability of isolated brain endothelial cells *in vitro*, and TNF also increases the diffusion of ammonia into astrocytes.⁴⁶

Neurosteroids

In patients with HE, expression of the 18 kDa translocator protein (also known as the peripheral-type benzodiazepine receptor) is thought to be upregulated in microglial cells that are activated by inflammation. Increased expression of this receptor results in increased mitochondrial synthesis of neuroactive steroids, which are also known as neurosteroids.⁴⁷

Evidence suggests that neurosteroids are involved in the pathogenesis of HE.⁴⁸ These compounds are synthesized in the central and peripheral nervous system, either from cholesterol or from steroid precursors (metabolites of steroid hormones produced in the gonads and adrenals). In the brain, neurosteroids are mainly produced by myelinating glial cells (such as astrocytes).⁴⁹ Neurosteroid synthesis occurs in the mitochondrial endoplasmic reticulum of astroglial cells. Translocator proteins are situated on the mitochondrial membrane in astrocytes and regulate neurosteroid synthesis.^{50,51} Ammonia and manganese, which accumulate in patients with liver failure, are thought to enhance neurosteroid synthesis by activating these translocator proteins.⁶ Findings from brain autopsies have shown an increased density of expression of this protein in patients with cirrhosis.^{52,53} In addition, Cagnin *et al.*⁴⁷ demonstrated increased densities of translocated protein expression in the brains of patients with MHE by using a specific ligand that binds to this protein in PET imaging studies.⁴⁷ Neurosteroids are positive allosteric modulators of the GABA_A receptor; they increase influx of chloride ions and thereby enhance GABAergic tone. These effects are responsible for some clinical sequelae in patients with type C HE.⁵⁴

Oxidative and nitrosative stress

Enhanced production of reactive nitrogen species (RNS) and reactive oxygen species (ROS) occurs in cultured astrocytes (isolated from rats) that are exposed to ammonia, inflammatory cytokines, hyponatremia or benzodiazepines.⁵⁵ This process is dependent on levels of calcium and occurs through *N*-methyl-D-aspartate receptor pathways.⁵⁶ Hilgier *et al.*⁵⁷ demonstrated overstimulation of *N*-methyl-D-aspartate receptors in the rat brain after intravenous administration of ammonium chloride. Acute swelling of astrocytes has also been observed when these cells are exposed to ROS or RNS *in vitro*.⁵⁸ In 2006, Albrecht and Norenberg proposed a 'Trojan horse' hypothesis to account for the toxic effect of glutamine in astrocytes.⁵⁹ These researchers suggested that glutamine formed in the cytoplasm enters the mitochondrial matrix and is cleaved to release ammonia while still inside the mitochondria. This intramitochondrial ammonia is then thought to mediate release of ROS and RNS through




Figure 2 | Management of patients with hepatic encephalopathy (HE). A tripartite strategy is useful in the management of patients with HE. Other potential causes of encephalopathy, such as CNS sepsis, cerebral edema and hypoxia, must be excluded and the precipitating cause of HE identified before a firm diagnosis of HE can be made. In patients with cirrhosis, factors such as sepsis, drugs and dietary protein overload can precipitate HE. When HE is suspected, simultaneous, empiric treatment for HE should be initiated to improve the patient’s symptoms. Any improvement in HE symptoms after initiation of therapy indicates that the diagnosis of HE is correct. A lack of improvement indicates that another explanation for the symptoms should be sought. *Predominantly observed in patients with acute liver failure.

calcium-dependent pathways.⁵⁹ Evidence indicating a close association and interplay between astrocyte swelling and ROS is now growing.⁵ Apart from astrocyte swelling, ROS are also involved in nitration of tyrosine residues in intracellular proteins.^{55,58} Tyrosine nitration affects transastrocytic substrate transport and selective degradation of the permeability of the blood–brain barrier, which ultimately promotes astrocyte swelling and cerebral edema.²⁹

Manganese

Manganese is a neurotoxin that preferentially accumulates in the basal ganglia. Manganese deposition has been detected by MRI in the basal ganglia of patients with cirrhosis and in rats with an extensive portacaval shunt^{61–63} and has been shown to resolve with normalization of liver function.^{64,65} Manganese is thought to induce changes in astrocytes of the basal ganglia that promote the formation of Alzheimer type II astrocytes. This neurotoxin is also involved in stimulation of translocator proteins on astrocytes, which further enhances neurosteroid synthesis and GABAergic tone.⁸ Preferential deposition of manganese in the basal ganglia might explain the Parkinsonian symptoms (such as tremors) seen in some patients with HE.⁶⁶

Diagnosis

The approach to HE comprises exclusion of other causes of encephalopathy, identification of the precipitating cause and a trial of empiric treatment for HE (Figure 2). A rapid response to this empiric treatment confirms a diagnosis of HE, whereas lack of response within 72 h

indicates that further treatment options should be considered (as discussed below).

Differential diagnosis and underlying causes

Several conditions have similar symptoms to HE (Figure 2) and exclusion of these causes of encephalopathy is imperative for the correct management of patients with HE. If patients show evidence of changes in mental status, exclusion of subdural hematoma is vital as patients with cirrhosis have coagulopathies and an increased risk of falls.⁶⁷ Cirrhosis is associated with an increased risk of sepsis, sepsis-related organ failure and death.⁶⁸ Medication-induced adverse effects are very common in patients with cirrhosis, as the liver is the site of first-pass metabolism for most drugs and this organ is dysfunctional in these patients. As well as excluding conditions that can mimic HE, diagnosis of this disease involves the identification of potential precipitating causes. These two processes are a key aspect of the management of patients with suspected HE. Most patients with chronic liver disease have at least one (and often multiple, coexisting) simultaneous precipitating factors capable of inducing an episode of HE.

Many different assessments, including brain imaging and neuropsychometric tests, can be used to diagnose HE (Table 1). OHE is conventionally graded by clinical scales such as the West Haven criteria.⁶⁹ MHE, by contrast, can only be diagnosed by specific neuropsychometric tests.¹ A wide spectrum of neurological and neuropsychological abnormalities exists in patients with cirrhosis, which stretches from no HE at one end to severe HE and coma at the other.⁷⁰

Table 1 | Advantages and disadvantages of diagnostic tests for hepatic encephalopathy

Diagnostic test	Advantages	Disadvantages
Serum levels of ammonia	Positively correlated with the severity of HE	Does not change approach to diagnose and manage HE Can be challenging to take appropriate blood samples in the clinic
Clinical scales for OHE		
West Haven criteria	Well-established classification criteria (in use for ≈30 years) Used in multiple studies of OHE	Interobserver variation influences test results (especially for low grades of HE)
HE Scoring Algorithm	Minimal variability in results between different test sites Characterizes low grades of HE	Time consuming (which may be a limiting factor in the outpatient setting)
Neuropsychometric tests ('paper and pencil' tests) for MHE		
Psychometric HE score	Specifically designed to diagnose subtle cognitive changes in patients with MHE Endorsed as the 'gold standard' by the Working Party at the 1998 World Congress of Gastroenterology, Vienna, Austria	Poor test of memory Difficult to interpret and score Excessive reliance on measuring fine motor skills Unpopular in USA (lack of US-specific normative data and availability)
Repeatable Battery for the Assessment of Neurological Status	Tests can be completed rapidly (within 25 min)	Difficult to interpret and score Excessive reliance on measuring fine motor skills
Computerized psychometric tests for MHE		
Inhibitory control test	Detects MHE with high sensitivity Validated against existing psychometric tests	Studies using this test have mostly been conducted in a single institution located in either Wisconsin or Virginia, USA
CDR system	Correlates well with neuropsychometric tests	Time consuming, which could be a limiting factor Trial run needed before formal testing
Neurophysiologic tests		
Critical flicker frequency	High sensitivity and specificity Correlates well with neuropsychometric tests Widely used in clinical trials	Lack of widespread availability in the USA to permit use in ambulatory patients
Electroencephalography	HE associated with slow frequency of electrical activity	Variable sensitivity for the diagnosis of HE (43–100%)
Brain imaging		
MRI	Multiple techniques available Identifies several brain abnormalities associated with HE (e.g. levels of glutamate)	Can be expensive (especially the newer techniques that show low grades of cerebral edema)
CT	Useful for excluding other causes of encephalopathy Identifies conditions that worsen HE (subdural hematoma or a cerebrovascular event)	Poor detection of low grades of cerebral edema in most patients with HE Risk associated with radiation exposure

Abbreviations: CDR, Cognitive Drug Research computerized assessment; HE, hepatic encephalopathy; MHE, minimal hepatic encephalopathy; OHE, overt hepatic encephalopathy.

Clinical scales for grading HE

A number of scales have been devised for the diagnosis of HE; the first of its kind was proposed by Parson-Smith and colleagues in 1957.⁷¹ For patients with moderate to severe HE, the Glasgow Coma Scale can also be employed.⁷²

West Haven criteria

In 1977, Conn *et al.*⁶⁹ developed the West Haven criteria (Table 1), which have been used in a number of studies of HE.⁶⁹ This scale semiquantitatively grades a patient's mental state by means of subjective assessments of behavior, intellectual function, alteration of consciousness and neuromuscular function. The original version of the West Haven criteria comprised four grades, ranging from grade 1 (which includes symptoms such as a trivial lack of awareness) through to grade 4 (which implies an unresponsive patient in a coma). However, the findings of studies utilizing this scale demonstrated substantial variability between observers in their assessments of low grades of HE. In 2004, Amodio and colleagues, therefore, proposed a modification to the West Haven criteria that

introduced objective scales for the assessment of the individual components of the criteria in patients with HE.^{73,74} Further studies are needed to determine whether this version of the West Haven criteria should be implemented for general use in patients with suspected HE.

Hepatic Encephalopathy Scoring Algorithm

Characterization of the different grades of HE is especially important in the design of therapeutic trials. The HE Scoring Algorithm (HESA) was originally devised by Hassanein *et al.*⁷⁵ for use in a multicenter study that assessed the utility of extracorporeal albumin dialysis in the treatment of patients with HE.⁷⁵ This algorithm is particularly useful for assessing patients with low grades of HE, as minimal variability was evident between the scores given at the different sites participating in the study (Table 1).⁷⁵

Neuropsychometric tests

Neuropsychometric tests (including 'paper and pencil' tests and computerized tests) are employed to identify impairments in domains such as visuo-spatial

Box 1 | The psychometric hepatic encephalopathy score

The psychometric hepatic encephalopathy score includes the following battery of tests: Number Connection Test A, measures concentration, mental tracking and visuo-motor speed; Number Connection Test B, measures concentration, mental tracking and visuo-motor speed (but with greater complexity than test A); Digit Symbol Test, measures psychomotor and visuomotor speed; Line Tracing Test, measures visuo-motor and visuo-spatial components (for both speed and accuracy); Serial Dotting Test, measures psychomotor speed. Impairment of >2 SD in two or more tests (of at least four tests) in this battery is necessary for a diagnosis of minimal hepatic encephalopathy.

functioning, attention, processing speed and response inhibition. Over time, these tests have proven to be sensitive to the changes associated with MHE. However, these tests are not without their limitations (Table 1).

PHES

The psychometric HE Score (PHES) is a battery of neuropsychometric tests that was specifically designed to diagnose the subtle cognitive changes that characterize MHE in patients with cirrhosis (Table 1 and Box 1).^{76,77} Normative data for comparison were initially obtained in Germany, followed by Italy and Spain.^{73,76,78} Abnormal test results are strongly correlated with changes found on functional brain neuroimaging scans. The Working Party of the 1998 World Congress of Gastroenterology, Vienna, Austria, endorsed this test as the official 'gold standard' for the diagnosis of MHE. Notably, apart from the PHES, no other psychometric tests for HE have been validated by comparisons with normative data. This lack of validation remains an important area for further research in the field of MHE. The PHES has failed to gain popularity in the USA, however, owing to the lack of US-specific normative data and limited availability of the testing system.

RBANS

The Repeatable Battery for the Assessment of Neurological Status (RBANS) was issued to diagnose neurocognitive disorders such as dementia, traumatic brain injury, stroke, multiple sclerosis and bipolar disorder in the USA. A subset of the RBANS tests is used in the USA instead of the PHES. This modified version of the RBANS was designed to focus specifically on the cognitive changes that occur in patients with OHE.⁷⁷ The modified RBANS test has now been used in multiple studies in the USA and has proven to be effective in screening patients for MHE.^{79,80} Like the PHES, the RBANS is a paper and pencil test that takes about 20–25 min to administer. In addition to the domains assessed in the PHES, the RBANS test scores patients' visual, verbal and working memory.

Computerized psychometric tests

A number of computerized psychometric tests have been developed in the past 5 years that, once approved by a large consensus group, have the potential to revolutionize the assessment of patients with HE.

Inhibitory control test

The inhibitory control test seems to be the most popular of the currently available computerized tests for HE.

This test assesses two different cognitive domains that are affected in patients with MHE—response inhibition and attention.^{81,82} The principle of this test is based on 'targets' and 'lures'. Patients are shown a series of different alphabet sequences that flash on the computer screen one after another, and are expected to respond when 'X' is followed by 'Y' and vice versa—a so-called 'target'. However, patients are told not to respond to a 'lure'—when 'X' followed by 'X' or 'Y' is followed by 'Y'. A lure response greater than five (out of 40 attempts) detects MHE with high sensitivity.^{81,82} This test has been validated against conventional standard psychometric tests and, in a trial of probiotic therapy for HE, has shown close correlations with other HE scores and improvements in test results in patients who responded to therapy.⁸² However, most studies that used the inhibitory control test have been published by a single group of investigators and have been conducted only in either Wisconsin or Virginia, USA. Nonetheless, this test shows promise and might ultimately be approved for the diagnosis of MHE.

CDR computerized assessment system

The eponymous computerized assessment system from Cognitive Drug Research Ltd (CDR), Goring-on-Thames, UK, was devised specifically for neuropsychiatric profiling of patients with cirrhosis and MHE.⁸³ This battery consists of seven tests that comprise over 50 parallel forms of each task and comprehensively measure power of attention, continuity of attention, quality of episodic memory, quality of continuous memory and speed of memory. This test has shown good correlation with the gold-standard PHES test and is popular in the UK.⁸³

Electrophysiological assessments*Critical flicker frequency test*

The critical flicker frequency test was validated for the assessment of patients with HE in 2002⁸⁴ and for the assessment of patients with HE who were undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement in 2009.⁸⁵ The principle of this test is based on the fact that retinal glial cells in patients with HE undergo similar changes (that is, swelling) to those seen in cerebral glial cells, termed hepatic retinopathy. The test involves showing the patient light pulses, initially at a frequency of 60 Hz, which is gradually reduced in 0.1 Hz decrements, once per second. The critical flicker frequency represents the frequency at which discrete light pulses are first perceived. The test results are not influenced by sex, occupation or education level, and are only slightly dependent on age. Furthermore, the test results correlate positively with those of paper and pencil neuropsychometric tests.^{84,85} Moreover, a critical flicker frequency of below 39 Hz diagnoses MHE with high sensitivity and specificity. This tool has been widely used to assess HE in therapeutic trials.

Electroencephalography

Electroencephalography is an excellent tool for diagnosing HE in the research setting. HE is associated with a decreased mean frequency of electrical activity in the brain, and the diagnostic sensitivity for HE of this

Table 2 | Brain imaging modalities for diagnosis of hepatic encephalopathy

MRI technique	Imaging abnormality	Clinical correlate
T1-weighted imaging	Bilateral, symmetrical, high-intensity signal in the basal ganglia (globus pallidus and substantia nigra)	Attributed to preferential deposition of manganese in the basal ganglia Found in patients with cirrhosis who have substantial portosystemic shunts No quantitative relation to severity of HE Reverses after liver transplantation
Proton spectroscopy (¹ H MRS)	Increase in glutamate and glutamine signals Decrease in myoinositol and choline signals	Homeostatic compensatory metabolic changes occur in the astrocytes of patients with chronic liver failure that prevent massive cerebral edema Changes seen on MRS imaging usually correlate with the severity of HE Changes resolve after liver transplantation
Magnetic transfer ratio	Mild, diffuse reduction in magnetic transfer ratio in the white matter	Reflects mild cerebral edema Reverses after liver transplantation
T2-weighted FLAIR sequence and diffusion weighted imaging	Diffuse increase in white matter signal intensity in the cerebral hemispheres and the corticospinal tract	Observed changes because of cerebral edema Could explain neurologic abnormalities in patients with cirrhosis Reverses after liver transplantation

Abbreviations: FLAIR, fluid attenuation inversion recovery; HE, hepatic encephalopathy; MRS, magnetic resonance spectroscopy.

finding ranges between 43% and 100% in published studies.⁷³ New advances in electroencephalography, such as artificial neural network expert system software and short epoch, dominant activity and cluster analysis, could prove useful for the diagnosis of HE, although they require further validation in clinical trials.⁸⁶

Brain imaging

Cerebral edema in patients with HE is increasingly being detected by MRI.³⁶ Many MRI techniques can identify low-grade cerebral edema (Table 2). A CT scan of the head is useful to identify conditions that could either mimic or exacerbate HE, such as subdural hematoma or a cerebrovascular event (Table 2).

Measurement of serum ammonia levels

Levels of arterial and venous ammonia correlate positively with the severity of HE.⁸⁷ However, routine measurement of ammonia levels in the blood is not recommended, as the results of the test would not change either the approach to diagnosis or management of a patient with suspected HE. Additionally, this test can be challenging to perform in the clinic, as the blood sample should be collected from a stasis-free vein (that is, without using a tourniquet and taking care not to cause turbulence or hemolysis) and must be immediately transported on ice to the laboratory to be analyzed within 20 min.

Treatment

Many treatment options are available for patients with OHE (as described below), but no evidence currently supports the treatment of MHE. Most patients show clinical signs of improvement in the symptoms of HE within 24–48 h of initiation of treatment (both empiric therapy and treatment of the underlying causes). Serum levels of ammonia might lag behind the clinical response. However, if HE persists after 72 h of treatment, the following possibilities must be explored: other causes of encephalopathy might have been missed or inadequately treated; a precipitating factor might have been missed, treated inadequately or remain uncorrected; effective empiric therapy has not been instituted or has been given to excess (in the case of lactulose, as discussed below).

Pharmacological therapy

Correction of the underlying factors that precipitate HE might in itself help to resolve the disease, but predicting a patient's response to treatment is difficult. Inadequate response to treatment can be due to a combination of factors. All patients should, therefore, receive empiric therapy for HE as other possible diagnoses are being excluded. Empiric therapy is based on the principle of reducing the production and absorption of ammonia in the gut—a number of agents are beneficial for this purpose (Box 2).

Nonabsorbable disaccharides

Nonabsorbable disaccharides include lactulose and lactitol (an analog of lactulose that is not available in USA).^{88–90} In addition to having a laxative effect, lactulose and lactitol reduce the colonic pH and interfere with mucosal uptake of glutamine in the gut, thereby reducing the synthesis and absorption of ammonia.⁹¹ Lactulose is considered the first-line therapy for HE. This agent can be administered orally through a nasogastric tube to a comatose or unresponsive patient or rectally through enemas. The usual oral dose of lactulose is about 15–30 ml given twice a day to induce 2–3 soft bowel movements daily. Abdominal bloating and a sweet taste in the mouth are the principal adverse effects associated with normal doses of lactulose.⁹² Overtreatment with lactulose, however, results in the serious adverse effects of severe dehydration, hyponatremia and worsening of HE, especially in patients treated in the intensive care unit.⁹³ Clinicians must be mindful of the adverse effects of lactulose overtreatment in patients with HE.

Antibiotics

Several antibiotics can be used as empiric treatment for HE (Figure 2 and Box 2). Rifaximin is a minimally absorbed oral antibiotic with few adverse effects and no reported drug–drug interactions. A large, multicenter study, published in 2010, demonstrated that remission of HE was prolonged in patients treated with rifaximin compared with those who did not receive this antibiotic.⁹⁴ Rifaximin received FDA approval in March 2010 for the treatment of HE (at an oral dose of 550 mg twice daily).

Box 2 | Options for long-term treatment of hepatic encephalopathy

- Lactulose (oral dose of 15–30 ml twice daily)^{88–91}
- Rifaximin (oral dose of 550 mg twice daily)⁹⁴
- Zinc repletion (zinc sulfate and zinc acetate, oral dose of 600 mg)^{105,106}
- Bromocriptine (oral dose of 15–60 mg daily)¹⁰⁷
- Sodium benzoate (oral dose 5 g twice daily)¹⁰⁸
- L-ornithine L-aspartate (oral dose of 6 g three times daily)^{109,110}
- Vegetable-based protein diet
- BCAA-enriched diet

Abbreviation: BCAA, branched-chain amino acid.

Neomycin was one of the first antibiotics to be investigated as a potential treatment for HE. This drug mainly works by inhibiting mucosal glutaminase in the intestine, which reduces ammonia production in the gut.⁶⁹ Neomycin inhibits ammoniagenic coliform bacteria that produce urease (an enzyme that converts urea into ammonia) and are prevalent in the gut. The main adverse effects of neomycin sulfate administration include ototoxic and nephrotoxic effects and intestinal malabsorption. The use of this antibiotic has declined over the past few years, owing to the availability of safer antibiotics such as rifaximin.

Nutritional interventions

Skeletal muscle metabolizes ammonia in patients with chronic liver disease.^{19–21} Loss of lean body mass depletes this ‘ammonia sink’ and increases the ammonia load to the brain, thereby worsening HE. A strong consensus, therefore, exists that patients with cirrhosis should receive a high-protein diet. The European Society for Parenteral and Enteral Nutrition recommended, in 2006, that patients with cirrhosis must eat at least 1.2 g/kg of protein daily.^{95,96} They also recommended that the diet of patients with cirrhosis should be supplemented with branched-chain amino acids (BCAAs) and vegetable protein once HE has developed.

Branched-chain amino acids

BCAAs have been studied extensively and a recent meta-analysis has shown that patients with cirrhosis who receive BCAAs are more likely to recover from HE than those who do not receive this supplement.⁹⁷ BCAAs improve levels of serum albumin, increase progression-free survival and reduce both the number of hospitalizations and the length of hospital stays in patients with cirrhosis.^{97–99} These amino acids can be administered orally as well as intravenously; however, their use can be limited by poor availability and high costs.

Vegetable-based protein

Vegetable-based protein is better tolerated by patients with cirrhosis than meat-based protein. Vegetable-based protein foods have a high fiber content, which increases intestinal transit time and colonic motility and enhances intestinal nitrogen clearance.⁹⁹ Vegetable protein also reduces colonic pH, which prevents ammonia from being absorbed in the gut. The adverse effects of a

predominantly vegetarian diet include abdominal bloating and flatulence. To reduce these effects and increase a patient’s protein intake vegetable protein can be combined with dairy products, such as milk and cheese.

Long-term management

Outpatient management of HE

After an episode of HE has resolved, patients with cirrhosis tend to remain on empiric therapy for an indefinite period of time or until they undergo liver transplantation. The goals of therapy at this stage are to prevent recurrent episodes of HE and to ensure a reasonable quality of life.¹⁰⁰

Lactulose and rifaximin are popular choices for ongoing therapy in patients who have experienced an episode of HE (Box 2). Adherence of patients to lactulose therapy on a long-term basis is limited by its gastrointestinal adverse effects. Patients must also be educated with regard to the need to monitor the consistency of their bowel movements and use appropriate dose titration when being treated with lactulose. Rifaximin, by contrast, has emerged as an effective treatment strategy to prevent recurrence of HE in a multicenter study published in 2010.⁹⁴ Patients who had previously experienced at least two episodes of HE and were in remission were randomly assigned to receive either rifaximin or placebo and were followed up for 6 months. More than 90% of participants in this study were treated with lactulose in addition to rifaximin or placebo. The patients in the rifaximin group maintained their remission from HE more effectively than did patients in the placebo group, and rifaximin was associated with improved tolerability and decreased adverse effects compared with placebo.⁹⁴ Rifaximin is, therefore, likely to dominate treatment strategy for HE in the future.

Persistent HE

Orthotopic liver transplantation is the ultimate solution for patients affected by HE. However, HE has lost ground as an indication for liver transplantation in the era of the Model for End-stage Liver Disease (MELD) score. Stewart *et al.*¹⁰¹ reported that the severity of HE before liver transplantation is inversely correlated with the duration of survival after transplantation, and that the prognosis of patients who undergo transplantation for HE is worse than that indicated by their MELD score.¹⁰¹ A crucial issue, therefore, is that the work-up of a patient who is eligible for liver transplantation should be initiated at the earliest opportunity after an acute episode of HE.

Surgical portosystemic shunting or TIPS placement worsens HE because ammonia in the gut circulation can then bypass first-pass metabolism in the liver and go directly to the brain.¹⁰² Symptoms of HE that result from portosystemic shunting are amenable to shunt closure or a reduction in stent diameter, but these procedures are indicated only if the patient is not a candidate for transplantation. Alternative treatments for the underlying condition that prompted shunt placement (that is, recurrent variceal bleeding or refractory ascites) should be considered to prevent the development of HE.

Conclusions

HE is a neuropsychiatric complication of cirrhosis. Ammonia is recognized as a crucial component in the pathogenesis of HE, but other factors such as inflammation, neurosteroids and manganese are also implicated in the development of the disease. OHE can be diagnosed clinically and mild to moderate grades of the disease might be present in a considerable proportion of ambulatory patients with cirrhosis. Patients with MHE have normal findings on clinical examination, but abnormal psychometric test results.

Several computerized psychometric tests are being developed to aid the clinical diagnosis of HE and enable clinicians to screen patients with cirrhosis for this condition in an outpatient setting. Serum levels of ammonia have limited value in the diagnosis of HE, despite being an indicator of disease severity. Empiric treatment should be started in all patients with OHE. The main goals of outpatient management of patients who have previously experienced an episode of HE is focused on the maintenance of remission and on ensuring that they have a reasonable quality of life. Rifaximin and lactulose have both received FDA approval for the maintenance of remission in patients who have previously been affected by HE. An early work-up for liver transplantation is beneficial for the management of patients with HE who are candidates for this procedure.

Approval of computerized psychometric tests by the Hepatic Encephalopathy Consensus group for the diagnosis of MHE is on the horizon. This approval will facilitate widespread implementation of screening of patients with cirrhosis for HE in an outpatient setting. Furthermore, cyclic GMP and related molecules hold promise as biomarkers of MHE, which could revolutionize the future diagnosis and management of these patients.^{103,104} Translational research that involves advanced MRI techniques and proton spectroscopy might resolve controversial issues in the pathogenesis of HE. Although preliminary studies have shown that patients with MHE derive benefit from treatment, results of large multicenter trials in this setting are awaited. Identification of a cost-effective and well-tolerated agent for the treatment of HE remains a challenge.

Review criteria

This Review is based on a literature search of MEDLINE and PubMed for original articles published between 1975 and 2010. The search terms used were: "hepatic encephalopathy", "porto-systemic encephalopathy", "ammonia" and "lactulose". All papers identified were English-language full-text papers. We also searched the reference lists of identified articles for further relevant papers.

1. Ferenci, P. *et al.* Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* **35**, 716–721 (2002).
2. Shawcross, D. L., Wright, G., Olde Damink, S. W. & Jalan, R. Role of ammonia and inflammation in minimal hepatic encephalopathy. *Metab. Brain Dis.* **22**, 125–138 (2007).
3. Shawcross, D. L., Davies, N. A., Williams, R. & Jalan, R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. *J. Hepatol.* **40**, 247–254 (2004).
4. Norenberg, M. D., Jayakumar, A. R., Rama Rao, K. V. & Panicker, K. S. New concepts in the mechanism of ammonia-induced astrocyte swelling. *Metab. Brain Dis.* **22**, 219–234 (2007).
5. Schliess, F., Görg, B. & Häussinger, D. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. *Biol. Chem.* **387**, 1363–1370 (2006).
6. Ahboucha, S. & Butterworth, R. F. The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy. *Metab. Brain Dis.* **22**, 291–308 (2007).
7. Qadri, A. M., Ogunwale, B. O. & Mullen, K. D. Can we ignore minimal hepatic encephalopathy any longer? *Hepatology* **45**, 547–548 (2007).
8. Talwalkar, J. A. & Kamath, P. S. Influence of recent advances in medical management on clinical outcomes of cirrhosis. *Mayo Clin. Proc.* **80**, 1501–1508 (2005).
9. Poordad, F. F. Review article: the burden of hepatic encephalopathy. *Aliment. Pharmacol. Ther.* **25** (Suppl. 1), 3–9 (2007).
10. Groeneweg, M. *et al.* Subclinical hepatic encephalopathy impairs daily functioning. *Hepatology* **28**, 45–49 (1998).
11. Prasad, S. *et al.* Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. *Hepatology* **45**, 549–559 (2007).
12. Bajaj, J. S. *et al.* Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. *Hepatology* **47**, 596–604 (2008).
13. Bajaj, J. S., Saeian, K., Hafeezullah, M., Hoffmann, R. G. & Hammeke, T. A. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. *Clin. Gastroenterol. Hepatol.* **6**, 1135–1139 (2008).
14. Bajaj, J. S. *et al.* The effect of fatigue on driving skills in patients with hepatic encephalopathy. *Am. J. Gastroenterol.* **104**, 898–905 (2009).
15. Kircheis, G. *et al.* Hepatic encephalopathy and fitness to drive. *Gastroenterology* **137**, 1706–1715.e9 (2009).
16. Bajaj, J. S. *et al.* Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. *Hepatology* **50**, 1175–1183 (2009).
17. Bustamante, J. *et al.* Prognostic significance of hepatic encephalopathy in patients with cirrhosis. *J. Hepatol.* **30**, 890–895 (1999).
18. Zieve, L. Pathogenesis of hepatic encephalopathy. *Metab. Brain Dis.* **2**, 147–165 (1987).
19. Cooper, A. J. & Plum, F. Biochemistry and physiology of brain ammonia. *Physiol. Rev.* **67**, 440–519 (1987).
20. Ytrebø, L. M. *et al.* Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. *Am. J. Physiol. Gastrointest. Liver Physiol.* **291**, G373–G381 (2006).
21. Olde Damink, S. W., Jalan, R. & Dejong, C. H. Interorgan ammonia trafficking in liver disease. *Metab. Brain Dis.* **24**, 169–181 (2009).
22. Hahn, M., Massen, O., Nencki, M. & Pavlov, I. Die Eck'sche fistel zwischen der unteren hohlvene und ihre folgen für den organismus [German]. *Arch. Exp. Pathol. Pharm.* **32**, 161–210 (1893).
23. Shawcross, D. L., Olde Damink, S. W., Butterworth, R. F. & Jalan, R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. *Metab. Brain Dis.* **20**, 169–179 (2005).
24. Phillips, G., Schwartz, R., Gabuzda, G. & Davidson, C. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. *N. Engl. J. Med.* **247**, 239–246 (1952).
25. Lockwood, A. H., Yap, E. W. & Wong, W. H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. *J. Cereb. Blood Flow Metab.* **11**, 337–341 (1991).
26. Thomas, J. W., Banner, C., Whitman, J., Mullen, K. D. & Freese, E. Changes in glutamate cycle enzyme mRNA levels in a rat model of hepatic encephalopathy. *Metab. Brain Dis.* **3**, 81–90 (1988).
27. Häussinger, D., Kircheis, G., Fischer, R., Schliess, F. & vom Dahl, S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? *J. Hepatol.* **32**, 1035–1038 (2000).
28. Cooper, A. J., McDonald, J. M., Gelbard, A. S., Gledhill, R. F. & Duffy, T. E. The metabolic fate of ¹³N-labeled ammonia in rat brain. *J. Biol. Chem.* **254**, 4982–4992 (1979).
29. Häussinger, D. & Schliess, F. Pathogenetic mechanisms of hepatic encephalopathy. *Gut* **57**, 1156–1165 (2008).
30. Tanigami, H. *et al.* Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during

- hyperammonemia in rats. *Neuroscience* **131**, 437–449 (2005).
31. Rose, C., Kresse, W. & Kettenmann, H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH. *J. Biol. Chem.* **280**, 20937–20944 (2005).
 32. Rose, C. Effect of ammonia on astrocytic glutamate uptake/release mechanisms. *J. Neurochem.* **97** (Suppl. 1), 11–15 (2006).
 33. Hertz, L., Murthy, C. R., Lai, J. C., Fitzpatrick, S. M. & Cooper, A. J. Some metabolic effects of ammonia on astrocytes and neurons in primary cultures. *Neurochem. Pathol.* **6**, 97–129 (1987).
 34. Córdoba, J., Sanpedro, F., Alonso, J. & Rovira, A. ¹H magnetic resonance in the study of hepatic encephalopathy in humans. *Metab. Brain Dis.* **17**, 415–429 (2002).
 35. Häussinger, D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. *Hepatology* **43**, 1187–1190 (2006).
 36. Rovira, A., Alonso, J. & Córdoba, J. MR imaging findings in hepatic encephalopathy. *AJNR Am. J. Neuroradiol.* **29**, 1612–1621 (2008).
 37. Shawcross, D. L. *et al.* Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. *Am. J. Physiol. Gastrointest. Liver Physiol.* **287**, G503–G509 (2004).
 38. Butterworth, R. F. Pathophysiology of hepatic encephalopathy: The concept of synergism. *Hepatol. Res.* **38**, S116–S121 (2008).
 39. Gregorios, J. B., Mozes, L. W. & Norenberg, M. D. Morphologic effects of ammonia on primary astrocyte cultures. II. Electron microscopic studies. *J. Neuropathol. Exp. Neurol.* **44**, 404–414 (1985).
 40. Norenberg, M. D. The role of astrocytes in hepatic encephalopathy. *Neurochem. Pathol.* **6**, 13–33 (1987).
 41. Shawcross, D. & Jalan, R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. *Cell. Mol. Life Sci.* **62**, 2295–2304 (2005).
 42. Häussinger, D. & Schliess, F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. *Neurochem. Int.* **47**, 64–70 (2005).
 43. Moldawer, L. L. *et al.* Cachectin/tumor necrosis factor- α alters red blood cell kinetics and induces anemia *in vivo*. *FASEB J.* **3**, 1637–1643 (1989).
 44. de Vries, H. E. *et al.* The influence of cytokines on the integrity of the blood-brain barrier *in vitro*. *J. Neuroimmunol.* **64**, 37–43 (1996).
 45. Didier, N. *et al.* Secretion of interleukin-1 β by astrocytes mediates endothelin-1 and tumour necrosis factor- α effects on human brain microvascular endothelial cell permeability. *J. Neurochem.* **86**, 246–254 (2003).
 46. Duchini, A. Effects of tumor necrosis factor- α and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells. *J. Investig. Med.* **44**, 474–482 (1996).
 47. Cagnin, A., Taylor-Robinson, S. D., Forton, D. M. & Banati, R. B. *In vivo* imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy. *Gut* **55**, 547–553 (2006).
 48. Ahboucha, S. & Butterworth, R. F. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. *Neurochem. Int.* **52**, 575–587 (2008).
 49. Baulieu, E. E. Neurosteroids: a novel function of the brain. *Psychoneuroendocrinology* **23**, 963–987 (1998).
 50. Papadopoulos, V. *et al.* Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. *Trends Pharmacol. Sci.* **27**, 402–409 (2006).
 51. Papadopoulos, V., Lecanu, L., Brown, R. C., Han, Z. & Yao, Z. X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. *Neuroscience* **138**, 749–756 (2006).
 52. Desjardins, P. & Butterworth, R. F. The “peripheral-type” benzodiazepine (omega 3) receptor in hyperammonemic disorders. *Neurochem. Int.* **41**, 109–114 (2002).
 53. Bélanger, M., Desjardins, P., Chatauret, N., Rose, C. & Butterworth, R. F. Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure. *J. Hepatol.* **42**, 694–699 (2005).
 54. Ahboucha, S., Coyne, L., Hirakawa, R., Butterworth, R. F. & Halliwell, R. F. An interaction between benzodiazepines and neuroactive steroids at GABA_A receptors in cultured hippocampal neurons. *Neurochem. Int.* **48**, 703–707 (2006).
 55. Murthy, C. R., Rama Rao, K. V., Bai, G. & Norenberg, M. D. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. *J. Neurosci. Res.* **66**, 282–298 (2001).
 56. Hermenegildo, C., Monfort, P. & Felipe, V. Activation of N-methyl-D-aspartate receptors in rat brain *in vivo* following acute ammonia intoxication: characterization by *in vivo* brain microdialysis. *Hepatology* **31**, 709–715 (2000).
 57. Hilgier, W., Anderzhanova, E., Oja, S. S., Saransaari, P. & Albrecht, J. Taurine reduces ammonia- and N-methyl-D-aspartate-induced accumulation of cyclic GMP and hydroxyl radicals in microdialysates of the rat striatum. *Eur. J. Pharmacol.* **468**, 21–25 (2003).
 58. Reinehr, R. *et al.* Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. *Glia* **55**, 758–771 (2007).
 59. Albrecht, J. & Norenberg, M. D. Glutamine: a Trojan horse in ammonia neurotoxicity. *Hepatology* **44**, 788–794 (2006).
 60. Schliess, F. *et al.* Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. *FASEB J.* **16**, 739–741 (2002).
 61. Mullen, K. D. & Jones, E. A. Natural benzodiazepines and hepatic encephalopathy. *Semin. Liver Dis.* **16**, 255–264 (1996).
 62. Mullen, K. D., Cole, M. & Foley, J. M. Neurological deficits in “awake” cirrhotic patients on hepatic encephalopathy treatment: missed metabolic or metal disorder? *Gastroenterology* **111**, 256–257 (1996).
 63. Rose, C. *et al.* Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. *Gastroenterology* **117**, 640–644 (1999).
 64. Naegele, T. *et al.* MR imaging and ¹H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation. *Radiology* **216**, 683–691 (2000).
 65. Aggarwal, A. *et al.* Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure. *Mov. Disord.* **21**, 1986–1990 (2006).
 66. Krieger, D. *et al.* Manganese and chronic hepatic encephalopathy. *Lancet* **346**, 270–274 (1995).
 67. Tsuji, H. *et al.* A case of liver cirrhosis associated with chronic subdural hematoma and hepatic encephalopathy [Japanese]. *Fukuoka Igaku Zasshi.* **82**, 528–532 (1991).
 68. Foreman, M. G., Mannino, D. M. & Moss, M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. *Chest* **124**, 1016–1020 (2003).
 69. Conn, H. O. *et al.* Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. *Gastroenterology* **72**, 573–583 (1977).
 70. Bajaj, J. S., Wade, J. B. & Sanyal, A. J. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. *Hepatology* **50**, 2014–2021 (2009).
 71. Parsons-Smith, B. G., Summerskill, W. H., Dawson, A. M. & Sherlock, S. The electroencephalograph in liver disease. *Lancet* **273**, 867–871 (1957).
 72. Jennett, B., Teasdale, G., Braakman, R., Minderhoud, J. & Knill-Jones, R. Predicting outcome in individual patients after severe head injury. *Lancet* **15**, 1031–1034 (1976).
 73. Montagnese, S., Amodio, P. & Morgan, M. Y. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. *Metab. Brain Dis.* **19**, 281–312 (2004).
 74. Amodio, P., Montagnese, S., Gatta, A. & Morgan, M. Y. Characteristics of minimal hepatic encephalopathy. *Metab. Brain Dis.* **19**, 253–267 (2004).
 75. Hassanein, T. I., Hilsabeck, R. C. & Perry, W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). *Dig. Dis. Sci.* **53**, 529–538 (2008).
 76. Weissenborn, K. *et al.* Neuropsychological characterization of hepatic encephalopathy. *J. Hepatol.* **34**, 768–773 (2001).
 77. Randolph, C. *et al.* Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int.* **29**, 629–635 (2009).
 78. RED Hepatic Encephalopathy [Spanish]. *Spanish normative data for hepatic encephalopathy* [online], <http://www.redeh.org/> (2010).
 79. Meyer, T., Eshelman, A. & Abouljoud, M. Neuropsychological changes in a large sample of liver transplant candidates. *Transplant. Proc.* **38**, 3559–3560 (2006).
 80. Sorrell, J. H., Zolnikov, B. J., Sharma, A. & Jinnai, I. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. *Psychiatry Clin. Neurosci.* **60**, 174–181 (2006).
 81. Bajaj, J. S. *et al.* Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. *Am. J. Gastroenterol.* **102**, 754–760 (2007).
 82. Bajaj, J. S. *et al.* Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. *Gastroenterology* **135**, 1591–1600 (2008).
 83. Mardini, H., Saxby, B. K. & Record, C. O. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. *Gastroenterology* **135**, 1582–1590 (2008).
 84. Kircheis, G., Wettstein, M., Timmermann, L., Schnitzler, A. & Häussinger, D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. *Hepatology* **35**, 357–366 (2002).
 85. Kircheis, G. *et al.* Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS

- implantation. *Eur. J. Gastroenterol. Hepatol.* **21**, 1383–1394 (2009).
86. Amodio, P. *et al.* Electroencephalographic analysis for the assessment of hepatic encephalopathy: comparison of non-parametric and parametric spectral estimation techniques. *Neurophysiol. Clin.* **39**, 107–115 (2009).
87. Ong, J. P. *et al.* Correlation between ammonia levels and the severity of hepatic encephalopathy. *Am. J. Med.* **114**, 188–193 (2003).
88. Morgan, M. Y., Alonso, M. & Stanger, L. C. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. *J. Hepatol.* **8**, 208–217 (1989).
89. Morgan, M. Y. & Hawley, K. E. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. *Hepatology* **7**, 1278–1284 (1987).
90. Morgan, M. Y., Hawley, K. E. & Stambuk, D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. *J. Hepatol.* **4**, 236–244 (1987).
91. van Leeuwen, P. A., van Berlo, C. L. & Soeters, P. B. New mode of action for lactulose. *Lancet* **1**, 55–56 (1988).
92. Bajaj, J. S. Management options for minimal hepatic encephalopathy. *Expert Rev. Gastroenterol. Hepatol.* **2**, 785–790 (2008).
93. Mullen, K. D., Amodio, P. & Morgan, M. Y. Therapeutic studies in hepatic encephalopathy. *Metab. Brain Dis.* **22**, 407–423 (2007).
94. Bass, N. M. *et al.* Rifaximin treatment in hepatic encephalopathy. *N. Engl. J. Med.* **362**, 1071–1081 (2010).
95. Plauth, M. *et al.* ESPEN Guidelines on Enteral Nutrition: Liver disease. *Clin. Nutr.* **25**, 285–294 (2006).
96. Mullen, K. D. & Dasarathy, S. Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma? *J. Hepatol.* **41**, 147–148 (2004).
97. Muto, Y. *et al.* Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin. Gastroenterol. Hepatol.* **3**, 705–713 (2005).
98. Als-Nielsen, B., Koretz, R. L., Kjaergard, L. L. & Gluud, C. Branched-chain amino acids for hepatic encephalopathy. *Cochrane Database of Systematic Reviews*, Issue 1. Art. No.: CD001939. doi:10.1002/14651858.CD001939 (2003).
99. Amodio, P. *et al.* Vegetarian diets in hepatic encephalopathy: facts or fantasies? *Dig. Liver Dis.* **33**, 492–500 (2001).
100. Bajaj, J. S. Review article: the modern management of hepatic encephalopathy. *Aliment. Pharmacol. Ther.* **31**, 537–547 (2010).
101. Stewart, C. A., Malinchoc, M., Kim, W. R. & Kamath, P. S. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. *Liver Transpl.* **13**, 1366–1371 (2007).
102. Fanelli, F. *et al.* Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. *AJR Am. J. Roentgenol.* **193**, 1696–1702 (2009).
103. Montoliu, C. *et al.* Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients. *J. Mol. Med.* **85**, 237–245 (2007).
104. Albrecht, J. Cyclic GMP in blood and minimal hepatic encephalopathy: fine-tuning of the diagnosis. *J. Mol. Med.* **85**, 203–205 (2007).
105. Marchesini, G., Fabbri, A., Bianchi, G., Brizi, M. & Zoli, M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. *Hepatology* **23**, 1084–1092 (1996).
106. Bresci, G., Parisi, G. & Banti, S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. *Eur. J. Med.* **2**, 414–416 (1993).
107. Morgan, M. Y., Jakobovits, A. W., James, I. M. & Sherlock, S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. *Gastroenterology* **78**, 663–670 (1980).
108. Sushma, S. *et al.* Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. *Hepatology* **16**, 138–144 (1992).
109. Kircheis, G. *et al.* Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. *Hepatology* **25**, 1351–1360 (1997).
110. Kircheis, G., Wettstein, M., Dahl, S. & Häussinger, D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. *Metab. Brain Dis.* **17**, 453–462 (2002).

Acknowledgments

Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.

Author contributions

R. Prakash and K. D. Mullen contributed equally to researching data for the article, to substantial discussion of the content, to writing the article, and to reviewing and/or editing the manuscript before submission.